- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01690312
Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy
Clinical Study to Assess the Acute and Chronic Effects of a High-DHA Fish Oil on Fasting and Post-Prandial Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study involves fasted and post-prandial components.
Fasted Study:
Participants will provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo] in Treatment Period I. Participants will again provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo, opposite to Treatment Period I] during Treatment Period II.
There will be a 4-week washout period during the two Treatment Periods.
Post-prandial study:
Participants will also complete a post-prandial study pre-and post-intervention during each Treatment Period.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Ontario
-
Guelph, Ontario, Canada, N1G 0B4
- Nutrasource Diagnostics Inc.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Be an adult between the ages of 18 and 70;
- Be a male or a post-menopausal female who has gone a minimum of one year since their last menses;
- Be taking Statin medication at a stable dose for a minimum of four weeks prior to study commencement [and whom have reached a target LDL level];
- Have elevated fasting triglyceride levels [greater than 1.5 mmol/L but less than 5.7 mmol/L];
- Have fasting blood glucose levels below the study cut-off [less than 7.0 mmol/L];
- Have a Body Mass Index (BMI) less than 35.0
- Be taking natural health products BUT agree to cease consumption during the study period and a 4-week pre-study washout prior to study commencement. Study participants will be allowed to consume a daily multivitamin if they have been doing so at a stable dose for a minimum of three months prior to study commencement.
Exclusion Criteria:
- Be younger than 18 years of age or older than 70 years of age;
- Be an adult pre- or peri-menopausal female;
- Not have taken Statin medication at a stable dose for a minimum of 4 weeks prior to study commencement;
- Have fasting triglyceride levels outside of study limits[ie/ less than 1.5 mmol/L or greater than 5.7 mmol/L];
- Have elevated fasting blood glucose levels [greater or equal to 7.0 mmol/L];
- Have high blood pressure [greater than 140/100]
- Have a Body Mass Index (BMI) equal to or greater than 35.0
- Have a pre-existing cardiovascular disease or illness, including angina, myocardial infarction, stroke, intermittent claudication or transient ischemic attack;
- Have a known allergy to fish and/or fish oil, olive oil, soy or Vitamin E;
- Be taking natural health products but are unwilling to cease consumption during the study period and a 4-week pre-study washout prior to study commencement;
- Consume more than two (2) fish meals on a weekly basis
- Consume excessive amounts of alcohol on a weekly basis [more than 10 alcoholic drinks per week];
- Anticipate or have planned surgery during the course of the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: 1 (Dietary Supplement - Fish Oil)
On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed. On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol. |
On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day.
Each capsule contains 1000 mg of fish oil [620 mg of DHA and 150 mg of EPA], providing a total daily dosage of 4000 mg of fish oil [3080 mg of DHA+EPA].
|
|
Expérimental: 2 (Placebo)
On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed. On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol. |
On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day.
Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Triglyceride [TG]
Délai: 0 and 4 weeks
|
Fasted and postprandial samples will be drawn (hourly up to 6 hours).
|
0 and 4 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Glucose
Délai: 0 and 4 weeks
|
Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).
|
0 and 4 weeks
|
|
Insulin
Délai: 0 and 4 weeks
|
Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).
|
0 and 4 weeks
|
|
Total cholesterol [TC]
Délai: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
High-density lipoprotein [HDL]
Délai: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Low-density lipoprotein [LDL]
Délai: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Very low-density lipoprotein [VLDL]
Délai: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Lipoprotein A
Délai: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Intermediate-density lipoprotein [IDL]
Délai: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Remnant Lipoproteins
Délai: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
High-sensitivity C-Reactive Protein [hs-CRP]
Délai: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Homocysteine
Délai: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Essential Fatty Acid Profile
Délai: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Apolipoprotein B
Délai: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
|
Apolipoprotein A-1
Délai: 0 and 4 weeks
|
A fasted blood sample will be taken.
|
0 and 4 weeks
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Alison Duncan, Ph.D., R.D., University of Guelph
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- Insuline
- Humains
- Maladie cardiovasculaire
- DHA
- L'huile de poisson
- Statines
- Glucose
- Triglycérides
- Postprandial
- Homocystéine
- APE
- Lipoprotéines
- Jeûné
- Apolipoprotéine B
- High-DHA
- Total cholesterol [TC]
- High-density lipoprotein [HDL2, HDL3]
- Low-density lipoprotein [LDL1+2+3+4]
- Lipoprotein A [Lp(a)]
- Intermediate-density lipoprotein (IDL)
- Very low-density lipoprotein (VLDL1+2, VLDL3)
- Remnant Lipoproteins
- High-sensitivity C-Reactive Protein [hs-CRP]
- Essential Fatty Acid Profile
- Apolipoprotein A-1
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 11-09-002
- 150038 (Health Canada)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .